Skip to content

Study · Non-randomized trial · n = 45 · 2013

3 results

Effect of a low dose of gonadotropin releasing hormone antagonist on in vitro fertilization outcomes.

Kerimoğlu OS, Ercan CM, Keskin U, Korkmaz C, Duru NK, Ergün A

Archives of gynecology and obstetrics23 Mar 2013Cited by 8 (Europe PMC)

PMID23525593 (opens in a new tab)DOI10.1007/s00404-013-2806-z (opens in a new tab)PepBankPUB-23525593
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In IVF/ICSI patients, gonadotropin consumption was lower with half-dose cetrorelix than with 0.25 mg/day (1,350 versus 2,213 U, p = 0.046).

    In plain wordsIn IVF/ICSI patients, gonadotropin consumption was lower with half-dose cetrorelix than with 0.25 mg/day.

    Peptide
    Cetrorelix
    Outcome
    DecreaseGonadotropin consumption
    Study

    n = 45

    Comparator
    Cetrorelix 0.25 mg/day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.125 mg/day · injectionAs given in this study (human).

    Measurements

    Gonadotropin consumption
    1350 U
    half dose
    Gonadotropin consumption
    2213 U
    0.25 mg/day

    Source sentences

    Summary
    The mean consumption of gonadotropins was significantly higher in patients receiving 0.25 mg/day of cetrorelix (2,213 vs. 1,350 U; p = 0.046).
    3 context sentences
    Summary · context
    In this study, 45 IVF/intracytoplasmic sperm injection patients were stimulated with recombinant follicle stimulation hormone from day 2 of the cycle.
    Summary · context
    Cetrorelix was injected daily from day 6 of gonadotropin administration.
    Summary · context
    Twenty-two patients received cetrorelix at a dose of 0.25 mg/day, whereas 23 participants received half dose.
  2. 02HumanNon-randomized trialEfficacy outcome

    In IVF/ICSI patients, pregnancy rates were similar with half-dose cetrorelix and 0.25 mg/day (47.8 versus 31.8%, p = 0.273).

    In plain wordsIn IVF/ICSI patients, pregnancy rates were similar with half-dose cetrorelix and 0.25 mg/day.

    Peptide
    Cetrorelix
    Outcome
    No significant changeClinical pregnancy rate
    Study

    n = 45

    Comparator
    Cetrorelix 0.25 mg/day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.125 mg/day · injectionAs given in this study (human).

    Measurements

    Clinical pregnancy rate
    47.8%
    half dose
    Clinical pregnancy rate
    31.8%
    0.25 mg/day

    Source sentences

    Summary
    The clinical pregnancy rates were similar in both groups (31.8 vs. 47.8 %; p = 0.273).
    3 context sentences
    Summary · context
    In this study, 45 IVF/intracytoplasmic sperm injection patients were stimulated with recombinant follicle stimulation hormone from day 2 of the cycle.
    Summary · context
    Cetrorelix was injected daily from day 6 of gonadotropin administration.
    Summary · context
    Twenty-two patients received cetrorelix at a dose of 0.25 mg/day, whereas 23 participants received half dose.
  3. 03HumanNon-randomized trialEfficacy outcome

    In IVF/ICSI patients, premature LH surge rates did not differ significantly between cetrorelix doses (13% with 0.125 mg/day versus 9.1% with 0.25 mg/day).

    In plain wordsIn IVF/ICSI patients, premature LH surge rates did not differ significantly between cetrorelix doses.

    Peptide
    Cetrorelix
    Outcome
    No significant changePremature LH surge
    Study

    n = 45

    Comparator
    Cetrorelix 0.25 mg/day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.125 mg/day · injectionAs given in this study (human).

    Measurements

    Premature LH surge
    13%
    0.125 mg/day
    Premature LH surge
    9.1%
    0.25 mg/day

    Source sentences

    Summary
    Premature LH surge was detected in 9.1 % of the patients receiving cetrorelix 0.25 mg/day and in 13 % of the patients receiving cetrorelix 0.125 mg/day (p > 0.05).
    3 context sentences
    Summary · context
    In this study, 45 IVF/intracytoplasmic sperm injection patients were stimulated with recombinant follicle stimulation hormone from day 2 of the cycle.
    Summary · context
    Cetrorelix was injected daily from day 6 of gonadotropin administration.
    Summary · context
    Twenty-two patients received cetrorelix at a dose of 0.25 mg/day, whereas 23 participants received half dose.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.